ChengDu Sheng Nuo Biotec Co Ltd. Stock Analysis 688117.SS

Cheng Du Sheng Nuo Biotec Co., Ltd. engages in the research, development, production and sale of polypeptide generic drug raw materials and preparation products. The company is headquartered in Chengdu, Sichuan and currently employs 1,605 full-time employees. The company went IPO on 2021-06-03. The firm's main business includes independent research and development, production and sales of peptide APIs and preparations, providing pharmaceutical research services for peptide innovative drugs, customized production services for peptide products and transfer services for peptide drug production technology for domestic and foreign pharmaceutical companies, providing original equipment manufacture processing of small molecule chemical drug levosimendan preparations and levosimendan API production, export and sales business. The firm's products target areas including immunity, digestive tract, antiviral, obstetrics and gynecology, diabetes, cardiovascular and cerebrovascular, rare diseases, orthopedics and others. The firm mainly conducts its business in domestic and foreign markets.